Perioperative management of cranial diabetes insipidus in a patient requiring a tracheostomy

2021 ◽  
Vol 14 (4) ◽  
pp. e239261
Author(s):  
Mairead Kelly ◽  
Misha Verkerk ◽  
Patrick Harrison ◽  
Richard Oakley

Cranial diabetes insipidus (DI), which can cause life-threatening dehydration, is treated with desmopressin, often intranasally. This is challenging in patients whose nasal airflow is altered, such as those requiring tracheostomy. We report the case of a patient, taking intranasal desmopressin for cranial DI, who underwent partial glossectomy, free-flap reconstruction and tracheostomy. Postoperatively, she could not administer nasal desmopressin due to reduced nasal airflow. She developed uncontrollable thirst, polyuria and hypernatraemia. Symptoms were relieved by switching to an enteric formulation. A literature review showed no cases of patients with DI encountering difficulties following tracheostomy. The Royal Society of Endocrinology recommends perioperative planning for such patients, but gives no specific guidance on medication delivery in the context of altered airway anatomy. Careful perioperative planning is required for head and neck patients with DI, particularly for those undergoing airway alteration that may necessitate a change in the mode of delivery of critical medications.

2018 ◽  
Vol 7 (7) ◽  
pp. G8-G11 ◽  
Author(s):  
S E Baldeweg ◽  
S Ball ◽  
A Brooke ◽  
H K Gleeson ◽  
M J Levy ◽  
...  

Cranial diabetes insipidus (CDI) is a treatable chronic condition that can potentially develop into a life-threatening medical emergency. CDI is due to the relative or absolute lack of the posterior pituitary hormone vasopressin (AVP), also known as anti-diuretic hormone. AVP deficiency results in uncontrolled diuresis. Complete deficiency can lead to polyuria exceeding 10 L/24 h. Given a functioning thirst mechanism and free access to water, patients with CDI can normally maintain adequate fluid balance through increased drinking. Desmopressin (DDAVP, a synthetic AVP analogue) reduces uncontrolled water excretion in CDI and is commonly used in treatment. Critically, loss of thirst perception (through primary pathology or reduced consciousness) or limited access to water (through non-availability, disability or inter-current illness) in a patient with CDI can lead to life-threatening dehydration. This position can be further exacerbated through the omission of DDAVP. Recent data have highlighted serious adverse events (including deaths) in patients with CDI. These adverse outcomes and deaths have occurred through a combination of lack of knowledge and treatment failures by health professionals. Here, with our guideline, we recommend treatment pathways for patients with known CDI admitted to hospital. Following these guidelines is essential for the safe management of patients with CDI.


2019 ◽  
Author(s):  
Sam Westall ◽  
Heather Sullivan ◽  
Sid McNulty ◽  
Sumudu Bujawansa ◽  
Prakash Narayanan

2019 ◽  
Author(s):  
Suhaniya Samarasinghe ◽  
Rebecca Scott ◽  
Michael J Seckl ◽  
Mike Gonzalez ◽  
Richard Harvey ◽  
...  

1991 ◽  
Vol 67 (792) ◽  
pp. 912-913 ◽  
Author(s):  
A. W. Kung ◽  
K. K. Pun ◽  
K. S. Lam ◽  
R. T. Yeung

1991 ◽  
Vol 54 (10) ◽  
pp. 937-938 ◽  
Author(s):  
S Teelucksingh ◽  
R Sellar ◽  
J R Seckl ◽  
C R Edwards ◽  
P L Padfield

1988 ◽  
Vol 64 (750) ◽  
pp. 300-302 ◽  
Author(s):  
D. G. Menzies ◽  
J. F. Shaw ◽  
D. M. Kean ◽  
I. W. Campbell

1983 ◽  
Vol 104 (4) ◽  
pp. 417-422 ◽  
Author(s):  
R. Takeda ◽  
Y. Hiraiwa ◽  
T. Hayashi ◽  
S. Yasuhara ◽  
E. Yanase ◽  
...  

Abstract. The very rare occurrence of an ADH-producing small cell carcinoma of the lung in a 52 year old male patient with cranial diabetes insipidus since childhood is described. In this case diabetes insipidus disappeared concomitantly with development of lung cancer and re-appeared with shrinkage of the lung tumour by radiation therapy. Further progressive expansion of the primary and metastatic tumours induced the syndrome of inappropriate ADH secretion once again (SIADH). This deterioration in the clinical course was reflected in the plasma levels of ADH and neurophysins. The existence of vasopressin in the tumour tissue was also demonstrated by means of an immunohistochemical staining technique combined with anti-vasopressin serum.


Sign in / Sign up

Export Citation Format

Share Document